Characterization of focal leptomeningeal extension in patients with brain metastases: A novel entity

脑转移患者局灶性软脑膜侵犯的特征:一种新的实体

阅读:1

Abstract

BACKGROUND: Classical leptomeningeal disease (cLMD) impacts the entire craniospinal axis, but isolated parenchymal metastases sometimes display focal leptomeningeal extension (fLME) without diffuse LMD elsewhere. We assessed whether patients with fLME can be managed with stereotactic radiation (SRS/SRT) as opposed to whole brain/craniospinal radiation without excess development of marginal recurrences or subsequent cLMD. METHODS: We identified 796 patients with 2,354 newly-diagnosed brain metastases (BrM) without cLMD at diagnosis managed at a tertiary center between 2007 and 2022. Each metastasis was assessed for fLME, defined as isolated leptomeningeal extension of an intact BrM without cytologic or radiographic evidence of cLMD. Multivariable Fine and Gray's models were constructed for the primary outcomes of local recurrence and cLMD development. RESULTS: Among 796 patients, 138 (17.3%) displayed evidence of fLME, corresponding to 185 of 2,354 (7.9%) BrM. Patients with versus without fLME did not display excess local recurrences (1-year rate: 4.5% vs. 8.2%, respectively, P = .14; multivariable HR 0.56 [95% CI 0.30-1.07], P = .08), including in lesions managed with SRS/SRT (1-year rate: 4.4% vs. 4.9%, respectively; P = .63; multivariable HR 1.21 [95% CI 0.58-2.50], P = .61). The presence of fLME was not a significant predictor of subsequent cLMD (1-year rate: 5.2% vs. 5.2%, P = .99; multivariable HR 0.87 [95% CI 0.44-1.71], P = .68), including following treatment with SRS/SRT (1-year rate: 6.2% vs. 4.1%, P = .83; multivariable HR 0.92 [95% CI 0.36-2.39], P = .87). CONCLUSIONS: We describe a novel entity, fLME, which displays patterns of intracranial failure similar to parenchymal BrM. Stereotactic approaches may be viable in this population.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。